AB-Biotics was founded in 2004 as a spin-off from the Universidad Autónoma de Barcelona (UAB) [Autonomous University of Barcelona] led by Miquel Àngel Bonachera and Sergi Audivert, currently executive directors and members of the company’s Board of Directors. It is now a leading biotechnology company, international in scope, which divides its activities into these two main business areas (probiotics and precision medicine) based on research, development, intellectual protection and distribution of its own exclusive biotechnology solutions through a company with a business model (B2B).
The company’s efforts are focused on these two areas:
- PROBIOTICS: The relationship between microbiota-pathology and mechanism of action is the key element to innovate and patent strains of the unique AB-Biotics collection.
- PRECISION MEDICINE: With the aim of improving the efficiency of medicines and optimising health expenses.
The pharmaceutical, dietary supplement and functional food industries are our main partners.
We have a team of highly qualified professionals in a variety of fields, including biotechnology, biochemistry, pharmacy, genetics and microbiology, to name a few.
All our teams work side by side with partners to meet all research, development and market challenges.
KANEKA & AB-BIOTICS
As of 2018, the international chemical company KANEKA CORPORATION became a shareholder in the company Now both companies are working together to continue advances in probiotic science.